No abstract available
Keywords:
melanoma; pembrolizumab; progression; repigmentation; vitiligo.
MeSH terms
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antineoplastic Agents, Immunological / adverse effects*
-
Disease Progression
-
Female
-
Humans
-
Melanoma / diagnostic imaging
-
Melanoma / drug therapy*
-
Melanoma / secondary*
-
Middle Aged
-
Skin Pigmentation / drug effects*
-
Time Factors
-
Treatment Outcome
-
Uveal Neoplasms / pathology*
-
Vitiligo / chemically induced*
-
Vitiligo / diagnosis
-
Vitiligo / physiopathology
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
pembrolizumab